Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
Key Highlights
- ➤NYSE notice cites $48.4 million 30-day average market capitalization
- ➤Stockholders’ deficit was approximately $(4.3) million as of June 30, 2026
- ➤Annovis will submit a compliance plan within 45 days
- ➤Company has nine months to regain compliance or face delisting proceedings
- ➤ANVS continues trading with a temporary “.BC” designation
MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on October 29, 2026, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders’ equity was less than $50 million.
The Notice does not affect the Company’s business operations or its reporting obligations with the Securities and Exchange Commission, and it does not conflict with or cause an event of default under any of the Company’s material debt or other agreements.
Get started
Create a free account to read the full story.